Cutler Investment Counsel LLC Has $4.19 Million Stock Position in Pfizer Inc. $PFE

Cutler Investment Counsel LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 172,749 shares of the biopharmaceutical company’s stock after selling 1,493 shares during the quarter. Cutler Investment Counsel LLC’s holdings in Pfizer were worth $4,187,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of PFE. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Pfizer by 69.0% during the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company’s stock worth $1,600,000 after purchasing an additional 25,785 shares in the last quarter. Elevation Point Wealth Partners LLC boosted its stake in Pfizer by 15.9% in the first quarter. Elevation Point Wealth Partners LLC now owns 16,809 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 2,311 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Pfizer by 55.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 2,606,123 shares of the biopharmaceutical company’s stock valued at $66,039,000 after buying an additional 928,180 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $24.72 on Tuesday. The business’s 50-day moving average price is $24.88 and its 200-day moving average price is $24.12. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82. The firm has a market capitalization of $140.52 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analysts Set New Price Targets

Several research firms recently weighed in on PFE. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley reduced their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.